Bone Metastasis in Differentiated Thyroid Cancer: A Spanish Study
Author Information
Author(s): Dueñas-Disotuar Suset, Piñar-Gutiérrez Ana, de Lara-Rodríguez Irene, Sastre-Marcos Julia, Anda-Apiñániz Emma, Oleaga-Alday Amelia, Galofré JC, Orois Aida, Alcázar-Lázaro Victoria, Martínez-Guasch Laia, Sánchez-Ragnarsson Cecilia, Gálvez-Moreno María Ángeles, Familiar-Casado Cristina, Martín-Hernández Tomás, Romero-Lluch Ana R.
Primary Institution: Department of Endocrinology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Hypothesis
What are the clinical characteristics, survival rates, and prognostic factors for patients with bone metastases from differentiated thyroid carcinoma?
Conclusion
Patients with differentiated thyroid carcinoma and bone metastases in Spain have a 5-year survival rate of 39.5% and a 10-year survival rate of 28.5%, with better outcomes associated with treatment using I131.
Supporting Evidence
- 52.6% of patients had bone metastases at the initial diagnosis of differentiated thyroid carcinoma.
- 39.5% of patients survived 5 years after diagnosis of bone metastases.
- Patients treated with I131 had a better survival outcome.
- 54.1% of patients in the study died during follow-up.
- 66.2% of patients had metastases in other locations at initial diagnosis.
Takeaway
This study looked at patients with thyroid cancer that spread to their bones and found that those treated with a specific medicine had better chances of living longer.
Methodology
A multicenter retrospective observational study was conducted, analyzing data from patients diagnosed with differentiated thyroid carcinoma and bone metastases between 1980 and 2022.
Potential Biases
Variability in treatment protocols across different centers may introduce bias in interpreting results.
Limitations
The study's observational and retrospective nature and relatively small sample size limit the ability to establish clear prognostic factors.
Participant Demographics
The cohort included 57.1% women, with a median age of 67 years at diagnosis of bone metastases.
Statistical Information
P-Value
p=0.015 for age ≥67 years, p=0.048 for lymph node metastases, p=0.027 for I131 treatment
Confidence Interval
95% CI 1.005-2.098 for lymph node metastases, 95% CI 0.304-0.931 for I131 treatment, 95% CI 1.142-3.47 for age ≥67 years
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website